NASDAQ:LVTX - Nasdaq - NL0015000AG6 - Common Stock - Currency: USD
NASDAQ:LVTX (2/21/2025, 8:00:00 PM)
0.9575
+0.02 (+2.41%)
The current stock price of LVTX is 0.9575 USD. In the past month the price decreased by -0.57%. In the past year, price decreased by -53.74%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
LAVA Therapeutics NV is an immuno-oncology company. The company is headquartered in Utrecht, Utrecht and currently employs 37 full-time employees. The company went IPO on 2021-03-29. The firm focuses of developing next generation Vdelta T cell engaging bispecific antibodies to fight cancer.
LAVA THERAPEUTICS NV
Yalelaan 60
Utrecht UTRECHT NL
Employees: 37
Company Website: https://www.lavatherapeutics.com/
Investor Relations: http://ir.lavatherapeutics.com/
Phone: 31630003035
The current stock price of LVTX is 0.9575 USD. The price increased by 2.41% in the last trading session.
The exchange symbol of LAVA THERAPEUTICS NV is LVTX and it is listed on the Nasdaq exchange.
LVTX stock is listed on the Nasdaq exchange.
10 analysts have analysed LVTX and the average price target is 2.38 USD. This implies a price increase of 148.56% is expected in the next year compared to the current price of 0.9575. Check the LAVA THERAPEUTICS NV stock analysts ratings, price target forecast and up-and down grades for more detailed information.
LAVA THERAPEUTICS NV (LVTX) has a market capitalization of 25.17M USD. This makes LVTX a Nano Cap stock.
LAVA THERAPEUTICS NV (LVTX) currently has 37 employees.
LAVA THERAPEUTICS NV (LVTX) has a support level at 0.95 and a resistance level at 1.01. Check the full technical report for a detailed analysis of LVTX support and resistance levels.
The Revenue of LAVA THERAPEUTICS NV (LVTX) is expected to decline by -38.83% in the next year. Check the estimates tab for more information on the LVTX EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
LVTX does not pay a dividend.
LAVA THERAPEUTICS NV (LVTX) will report earnings on 2025-03-20, after the market close.
LAVA THERAPEUTICS NV (LVTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.03).
The outstanding short interest for LAVA THERAPEUTICS NV (LVTX) is 0.16% of its float. Check the ownership tab for more information on the LVTX short interest.
ChartMill assigns a fundamental rating of 2 / 10 to LVTX. LVTX may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months LVTX reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS increased by 46.35% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -33.16% | ||
ROE | -83.78% | ||
Debt/Equity | 0.18 |
ChartMill assigns a Buy % Consensus number of 80% to LVTX. The Buy consensus is the average rating of analysts ratings from 10 analysts.
For the next year, analysts expect an EPS growth of 26.55% and a revenue growth -38.83% for LVTX